Myovant Sciences Ltd (NYSE:MYOV) Given Average Recommendation of “Buy” by Analysts

Share on StockTwits

Myovant Sciences Ltd (NYSE:MYOV) has been assigned an average rating of “Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $24.50.

Several analysts have issued reports on the company. Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a research note on Friday, September 6th. ValuEngine raised Myovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Leerink Swann assumed coverage on Myovant Sciences in a research note on Monday, August 19th. They issued an “outperform” rating and a $26.00 target price for the company. Svb Leerink assumed coverage on Myovant Sciences in a research note on Monday, August 19th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, Zacks Investment Research lowered Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday.

Shares of MYOV opened at $4.83 on Monday. The stock has a 50 day simple moving average of $6.40 and a two-hundred day simple moving average of $11.25. The company has a quick ratio of 3.42, a current ratio of 3.42 and a debt-to-equity ratio of 1.24. Myovant Sciences has a 1 year low of $4.57 and a 1 year high of $26.02.

Myovant Sciences (NYSE:MYOV) last issued its earnings results on Tuesday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $0.06. On average, equities research analysts forecast that Myovant Sciences will post -3.13 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Atria Investments LLC lifted its position in Myovant Sciences by 87.9% in the second quarter. Atria Investments LLC now owns 22,915 shares of the company’s stock valued at $162,000 after purchasing an additional 10,720 shares during the last quarter. Platinum Investment Management Ltd. raised its holdings in shares of Myovant Sciences by 62.7% during the second quarter. Platinum Investment Management Ltd. now owns 238,398 shares of the company’s stock valued at $2,158,000 after acquiring an additional 91,846 shares in the last quarter. First Manhattan Co. raised its holdings in shares of Myovant Sciences by 2,146.6% during the second quarter. First Manhattan Co. now owns 400,000 shares of the company’s stock valued at $3,620,000 after acquiring an additional 382,195 shares in the last quarter. United Services Automobile Association bought a new position in shares of Myovant Sciences during the second quarter valued at approximately $690,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Myovant Sciences by 33.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,086,893 shares of the company’s stock valued at $9,836,000 after acquiring an additional 274,745 shares in the last quarter. Hedge funds and other institutional investors own 40.29% of the company’s stock.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Article: Most Volatile Stocks

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.